RT Journal Article
T1 β-blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy.
A1 Sturm, Gunter Johannes
A1 Herzog, Sereina Annik
A1 Aberer, Werner
A1 Alfaya Arias, Teresa
A1 Antolin-Amerigo, Dario
A1 Bonadonna, Patrizia
A1 Boni, Elisa
A1 Bożek, Andrzej
A1 Chełmińska, Marta
A1 Ernst, Barbara
A1 Frelih, Nina
A1 Gawlik, Radoslaw
A1 Gelincik, Asli
A1 Hawranek, Thomas
A1 Hoetzenecker, Wolfram
A1 Jimenez Blanco, Aranzazu
A1 Kita, Karolina
A1 Kendirlinan, Reşat
A1 Košnik, Mitja
A1 Laipold, Karin
A1 Lang, Roland
A1 Marchi, Francesco
A1 Mauro, Marina
A1 Nittner-Marszalska, Marita
A1 Poziomkowska-Gęsicka, Iwona
A1 Pravettoni, Valerio
A1 Preziosi, Donatella
A1 Quercia, Oliviero
A1 Reider, Norbert
A1 Rosiek-Biegus, Marta
A1 Ruiz-Leon, Berta
A1 Schrautzer, Christoph
A1 Serrano, Pilar
A1 Sin, Aytül
A1 Sin, Betül Ayşe
A1 Stoevesandt, Johanna
A1 Trautmann, Axel
A1 Vachova, Martina
A1 Arzt-Gradwohl, Lisa
K1 ACE inhibitor
K1 Adverse event
K1 Beta-blocker
K1 Systemic insect sting reaction
K1 Venom immunotherapy
AB There is controversy whether taking β-blockers or ACE inhibitors (ACEI) is a risk factor for more severe systemic insect sting reactions (SSR) and whether it increases the number or severity of adverse events (AE) during venom immunotherapy (VIT). In this open, prospective, observational, multicenter trial, we recruited patients with a history of a SSR and indication for VIT. The primary objective of this study was to evaluate whether patients taking β-blockers or ACEI show more systemic AE during VIT compared to patients without such treatment. In total, 1,425 patients were enrolled and VIT was performed in 1,342 patients. Of all patients included, 388 (27.2%) took antihypertensive (AHT) drugs (10.4% took β-blockers, 11.9% ACEI, 5.0% β-blockers and ACEI). Only 5.6% of patients under AHT treatment experienced systemic AE during VIT as compared with 7.4% of patients without these drugs (OR: 0.74, 95% CI: 0.43-1.22, p = 0.25). The severity of the initial sting reaction was not affected by the intake of β-blockers or ACEI (OR: 1.14, 95% CI: 0.89-1.46, p = 0.29). In total, 210 (17.7%) patients were re-stung during VIT and 191 (91.0%) tolerated the sting without systemic symptoms. Of the 19 patients with VIT treatment failure, 4 took β-blockers, none an ACEI. This trial provides robust evidence that taking β-blockers or ACEI does neither increase the frequency of systemic AE during VIT nor aggravate SSR. Moreover, results suggest that these drugs do not impair effectiveness of VIT. 
PB Wiley
YR 2021
FD 2021-01-20
LK http://hdl.handle.net/10668/17198
UL http://hdl.handle.net/10668/17198
LA en
NO Sturm GJ, Herzog SA, Aberer W, Alfaya Arias T, Antolín-Amérigo D, Bonadonna P, et al. β-blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy. Allergy. 2021 Jul;76(7):2166-2176
DS RISalud
RD Apr 7, 2025